Citations

Mayo Clinic

Clear

22 citation(s) found for "Nahi, Hareth".

Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib
Kumar, Shaji , LaPlant, Betsy, Reeder, Craig B. , Halvorson, Alese E. , Bergsagel, P. Leif , Thompson, Melanie , Crawley, Jamie , Kapoor, Prashant , Stewart, Keith, Hayman, Suzanne R. , Hwa, Yi L. , Dingli, David , Lin, Yi , Rivera, Candido E., Lacy, Martha Q. , Nahi, Hareth , Bergsagel, P. Leif , Kumar, Shaji K , LaPlant, Betsy R, Mıkhael, Joseph , Roy, Vivek , Buadi, Francis K. , Gertz, Morie A. , Dispenzieri, Angela , Gonsalves, Wilson I. , Witzig, Thomas E. , Ailawadhi, Sikander , Go, Ronald S. , Rajkumar, S. Vincent , Dingli, David , Lin, Yi , Nahi, Hareth

Blood | October 4, 2016 | Volume: 128 | Issue: 20 | Pages: 2415-2422

10.1182/blood-2016-05-717769 | PMID 27702799 Get It

Key Points The combination of ixazomib and dexamethasone has clinical activity in patients with relapsed and or refractory multiple myeloma. Higher dose of ixazomib leads to improved response rates but with higher rates of treatment related adverse events.
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma
Avet‐Loiseau, Hervé , Dimopoulos, Meletios Α. , Špıčka, Ivan , Masszi, Tamás , Hájek, Roman , Rosiñol, Laura , Mihaylov, Georgi , Maisnar, Vladimír , Mateos, María‐Victoria , Wang, Michael , Niesvizky, Rubén, Oriol, Albert , Minařík, Jiří , Palumbo, Antonio , Bensinger, William, Kukreti, Vishal , Ben‐Yehuda, Dina, Stewart, A. Keith, Obreja, Mihaela, Moreau, Philippe , Nahi, Hareth , Goranova‐Marinova, Veselina , Fonseca, Rafaël , Siegel, David S. , Goranova-Marinova, Vesselina S , Jakubowiak, Andrzej , Hajek, Roman , Dimopoulos, Meletios A , Moreau, Philippe , Masszi, Tamas , Nahi, Hareth , Oriol, Albert

Blood | July 21, 2016 | Volume: 128 | Issue: 9 | Pages: 1174-1180

10.1182/blood-2016-03-707596 | PMID 27439911 Get It

Key Points KRd has a favorable benefit-risk profile compared with Rd, regardless of baseline cytogenetic risk status, in patients with relapsed MM. KRd improves but does not abrogate the poor prognosis associated with high-risk cytogenetics in patients with relapsed MM.